Comparing PI3K/Akt Inhibitors Used in Ovarian Cancer Treatment

Frontiers in Pharmacology - Switzerland
doi 10.3389/fphar.2020.00206
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Frontiers Media SA

Related search

Preclinical Testing of PI3K/AKT/mTOR Signaling Inhibitors in a Mouse Model of Ovarian Endometrioid Adenocarcinoma

Clinical Cancer Research
Cancer ResearchOncology
2011English

Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2014English

Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer

Clinical Cancer Research
Cancer ResearchOncology
2009English

B7-H3 Induces Ovarian Cancer Drugs Resistance Through an PI3K/AKT/BCL-2 Signaling Pathway

Cancer Management and Research
Oncology
2019English

MicroRNA-101 Inhibits Growth and Metastasis of Human Ovarian Cancer Cells by Targeting PI3K/AKT

Archives of Medical Science
Medicine
2019English

The Role of the PTEN/PI3K/Akt Pathway on Prognosis in Epithelial Ovarian Cancer: A Meta-Analysis

Oncologist
Cancer ResearchMedicineOncology
2014English

PARP Inhibitors in Ovarian Cancer

2013English

Current State and Perspectives of Checkpoint Inhibitors in Ovarian Cancer Treatment

Memo - Magazine of European Medical Oncology
OncologyHematology
2020English

Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy